Sun Pharmaceutical Industries Ltd has launched ILUMYA® (Tildrakizumab) in India, a globally approved innovative biologic therapy used to treat adults with moderate-to-severe plaque psoriasis. The drug has already been used widely in the US and across 35 countries, where dermatologists recognise it for its strong and long-lasting results.

What Makes ILUMYA® Different?

ILUMYA is a novel biologic medicine designed to target IL-23, a key protein involved in psoriasis. By blocking this protein, the drug reduces inflammation and helps clear skin more effectively and safely than older treatments.

Sun Pharma’s Managing Director Kirti Ganorkar said the therapy offers a reliable new option for patients who struggle with traditional treatments. ILUMYA has shown consistent improvement soon after treatment begins and maintains results for years.

Clinical Study Results in India

Sun Pharma conducted a clinical trial in India with 115 patients, and the results were strong:

• 75% skin clearance achieved by
  • 62.3% of patients at Week 12
  • 83.3% at Week 16
  • 93.9% at Week 28
• 90% skin clearance achieved by
  • 26.3% of patients at Week 12
  • 50% at Week 16
  • 78.1% at Week 28

Patients received only 3 injections over 16 weeks, and the treatment was well-tolerated with no safety concerns.

Dermatologist Dr B. S. Chandrashekar, who participated in the Phase-3 trial, highlighted the drug’s impressive long-term effectiveness and improvements in patient quality of life.

Why India Needs a New Psoriasis Therapy

Plaque psoriasis is a chronic autoimmune condition that causes thick, scaly skin patches.

• Globally, it affects 2–3% of people.
• In India, it affects 0.44–2.8% of the population.

Many Indian patients do not get good long-term control with older treatments due to side effects, toxicity concerns, or the need for frequent monitoring. This leads to repeated flare-ups and impacts physical and mental well-being. ILUMYA helps address this gap by offering high, sustained skin clearance with fewer dosing and monitoring requirements.

Also Read: NSE Revises Quantity Freeze Limits for Fin Nifty: What You Need to Know?

About ILUMYA®

ILUMYA is a monoclonal antibody that blocks the IL-23 pathway to reduce inflammation.
It is approved in the US based on two major Phase-3 trials with more than 1,800 patients across 200 clinical sites. It is recommended for adults who need systemic therapy or phototherapy.

About Sun Pharma

Sun Pharma is India’s largest pharmaceutical company and a global leader in speciality medicines. Its products are trusted in over 100 countries, and its speciality portfolio, covering dermatology, ophthalmology, and oncology, accounts for 20% of its sales.

Sun Pharma Share Price Movement

Sun Pharmaceutical Industries share price (NSE: SUNPHARMA) is trading at ₹1,827.10, down 0.25% today. The stock opened at ₹1,841 and moved between a high of ₹1,849 and a low of ₹1,823.10. Sun Pharma has a market capitalisation of ₹4.38 lakh crore, a P/E ratio of 59.80, and a dividend yield of 0.88%. The stock’s 52-week range is between ₹1,548 on the lower end and ₹1,910 on the higher end.

Conclusion

With ILUMYA’s India launch, Sun Pharma introduces a globally trusted, long-lasting, and targeted biologic therapy for plaque psoriasis. This marks a major step forward in giving Indian patients access to safer and more effective long-term treatment options.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.